Rocket Pharmaceuticals (RCKT) – KRESLADI PDUFA March 28, 2026 and the post-CRL run-up

From CRL and Danon shock to a binary March 28 PDUFA

Rocket Pharmaceuticals is one of the purest public plays on ex vivo gene therapy in rare disease. Its lead program KRESLADI (RP-L201) targets severe leukocyte adhesion deficiency type I (LAD-I), a catastrophic pediatric immune deficiency where untreated children face recurrent life-threatening infections and a high risk of death in early childhood. After an initial BLA submission and a bruising Complete Response Letter (CRL) focused on manufacturing and CMC issues, Rocket resubmitted the file in September 2025; the FDA accepted it with Priority Review and set a new action date of March 28, 2026.

The clinical story in LAD-I is unusually clean for a small gene-therapy company. Across the pivotal programme, the company has reported 100% survival through follow-up of up to seven years, resolution or marked improvement of serious infections and durable CD18 expression in treated children. At the same time, the regulatory bar is unforgiving: KRESLADI is a bespoke autologous product for an ultra-rare indication, with a complex manufacturing chain, and the agency has already demonstrated its willingness to send Rocket back to the lab for more process and validation work.

2025 was also dominated by another story: Rocket’s gene therapy for Danon disease, where a patient death and serious adverse events led to an FDA clinical hold, programme restructuring and ultimately a far more cautious stance from investors on the entire platform. Combined with the KRESLADI CRL and a broad derating in the gene-therapy complex, RCKT went from being a high-expectation rare-disease leader to a controversial, heavily shorted name now trading at a fraction of its former market cap.

In what follows we walk through the LAD-I data and regulatory path, the Danon reset, the financial and ownership picture and how the stock has traded into and out of key events. Then we sketch a bull case and a bear case, with particular focus on how traders might think about the run-up into the March 28 decision window and the months that follow.

LAD-I and the logic behind KRESLADI

Leukocyte adhesion deficiency type I is a monogenic immune disorder caused by bi-allelic loss-of-function mutations in ITGB2, the gene encoding the β2-integrin CD18. Without functional CD18, neutrophils and other leukocytes cannot adhere properly to the vascular endothelium and migrate into tissues, which leads to extreme susceptibility to bacterial and fungal infections, poor wound healing, delayed umbilical cord separation and life-threatening sepsis in infancy. Severe LAD-I (the population targeted by Rocket) is ultra-rare: estimates count a few hundred known patients worldwide, with mortality in early childhood common in the absence of curative treatment.

The only established curative option today is allogeneic haematopoietic stem-cell transplantation (HSCT), which carries well-known risks: donor matching constraints, graft-versus-host disease, transplant-related mortality and long-term immune complications. KRESLADI aims to replace this with an autologous, ex vivo gene-therapy approach: CD34+ haematopoietic stem cells are harvested from the patient, transduced ex vivo with a lentiviral vector carrying a functional ITGB2 cassette, and reinfused after conditioning. In principle, this restores CD18 expression on neutrophils and other leukocytes, enabling normal adhesion and immune function.

That mechanistic story – single gene, clear pathophysiology, autologous correction – is exactly the kind of use case regulators have been willing to support in other ex vivo gene therapies, from ADA-SCID to metachromatic leukodystrophy and β-thalassemia. The flip side is that manufacturing quality, vector consistency and long-term follow-up are non-negotiable, and that is where the first KRESLADI BLA stumbled.

What went wrong the first time, and what is different now

Bottom line: the efficacy story in LAD-I looks robust; the outstanding questions reside in manufacturing reliability, inspection outcomes and whether the FDA is satisfied that long-term safety and vector behaviour are sufficiently characterised.

Why the Danon episode still hangs over the stock

Parallel to LAD-I, Rocket has pursued gene therapy for Danon disease, a rare X-linked cardiomyopathy driven by LAMP2 deficiency. The programme generated meaningful excitement in the earlier days of the gene-therapy trade – an ultra-orphan, high-mortality cardiac indication with dramatic unmet need. But in 2024–2025, safety events including a patient death and serious adverse events triggered an FDA clinical hold and forced Rocket to halt enrolment and undertake a deep investigation.

The company has since re-designed the programme, including exploration of alternative dosing and delivery strategies, and resumed some development work. However, from a trading perspective, much of the “platform premium” that Rocket once enjoyed has evaporated: investors now treat the Danon asset as a highly uncertain, longer-dated optionality play rather than a near-term value driver.

This matters for KRESLADI because:

– It colours how investors perceive management’s risk tolerance and safety culture.
– It amplifies concerns that regulators may look more closely at any systemic gene-therapy safety signals across programmes.
– It reduces enthusiasm for paying up for the rest of the pipeline until LAD-I is de-risked and real revenues appear.

In practical terms, it helps explain why RCKT trades closer to distressed territory than to a typical “late-stage, first-in-class gene therapy with RMAT and RPD designations”.

Cash into 2027, but more equity almost certainly ahead

On the financial side, Rocket entered late 2025 with a surprisingly strong balance sheet for a sub-billion-dollar biotech. As of 30 September 2025, the company reported roughly $659M in cash, cash equivalents and marketable securities, and guided that this should fund operations into 2027, even after taking into account the manufacturing remediation work and a focused pipeline.

That runway is the result of substantial prior capital raises plus a 2025 strategic reorganisation that reduced headcount and narrowed Rocket’s focus on the highest-priority assets, notably KRESLADI and the re-scoped Danon programme. The restructuring came at a cost – including layoffs and programme deprioritisations – but it gave management a credible story for surviving at least one full commercial launch cycle without immediately tapping the market again.

That said, even a successful KRESLADI launch in an ultra-rare indication is unlikely to turn Rocket cash-flow positive in the near term. Commercial build-out (centres of excellence, reimbursement infrastructure, manufacturing scaling, patient-finding) plus continued investment in Danon and other programmes means that:

– Equity raises are very likely over a multi-year horizon; the main uncertainty is the timing (pre- vs post-PDUFA, pre- vs post-PRV sale).
– The magnitude of dilution depends heavily on whether Rocket can monetise a PRV and secure strong payer support in LAD-I.

For traders, this means the run-up into March 28 is not simply about the binary probability of approval, but also about expectations for post-decision financing and how much of that risk is already in the price.

Who is steering the ship?

Rocket is led by Gaurav Shah, M.D., a physician-executive with a deep background in cell and gene therapy. Before founding Rocket, Shah held senior roles at Novartis, where he worked on CAR-T and lentiviral programmes including the landmark Kymriah launch, and at other biopharma companies in oncology and rare disease. That background gives Rocket credibility with regulators, partners and specialist investors – but it also means the bar for operational execution is high.

On the ownership side, RCKT is dominated by institutional and specialist healthcare funds. Filings show significant positions from long-only funds and crossover investors, with insiders owning a smaller but non-trivial share of the company. Short interest is elevated compared with many peers, reflecting a crowded bear case around gene-therapy risk, regulatory uncertainty and long-dated Danon optionality.

From a governance perspective, the board includes experienced biotech and financial executives, and Rocket has built out manufacturing and quality leadership as part of the post-CRL remediation. Still, investors will be judging the company primarily on one metric over the next twelve months: can it execute a clean approval and early launch in LAD-I without further CMC surprises?

How the stock has traded into and out of key 2025–2026 events

Looking back over the last eighteen to twenty-four months, RCKT’s tape reads like a case study in how quickly sentiment can turn in high-beta gene-therapy names:

– Early 2025: optimism around both LAD-I and Danon, with RCKT trading in a substantially higher range before the first storm clouds (trial safety events, questions around CMC and manufacturing) appeared.
– January 2025: the KRESLADI CRL crystallises CMC risk and triggers a sharp repricing; some investors question whether the platform and manufacturing base are fit for purpose.
– Mid-2025: Danon safety events and the clinical hold compound the damage. Rocket announces a strategic reorganisation, cuts staff and narrows focus; the stock derates alongside peers in a broader gene-therapy sell-off.
– Late 2025: resubmission of the KRESLADI BLA and acceptance with Priority Review give the name a new focal point – the March 28, 2026 PDUFA – but the bounce is relatively muted compared with pre-CRL levels.
– Early 2026: the stock trades more like a broken growth story than a standard “late-stage gene therapy into PDUFA” setup, with considerable short interest and a community of long-term believers offset by deeply sceptical bears.

For run-up traders, that history cuts both ways. On the one hand, a lot of bad news has already been digested; on the other, the market has a fresh memory of how painful it can be when gene-therapy expectations collide with regulatory caution and idiosyncratic safety issues.

What could go right and what could still go very wrong

What traders and investors should track

Heading into the March 28 action date, the most important things to watch are:

– Any additional FDA communication on KRESLADI, including label negotiation signals, new safety observations or CMC-related feedback in public documents or company guidance.
– Updated disclosures from Rocket on manufacturing readiness, site activation and payer engagement – especially any hints of unexpected bottlenecks.
– Changes in institutional ownership and short interest as specialist funds refine their risk positioning into the event.
– Broader macro sentiment towards gene therapy and rare-disease launches, including FDA decisions in other ex vivo products that might colour perceptions of risk across the class.

After the decision, the focus will shift quickly to: the actual label; any boxed warnings or REMS requirements; the initial cadence of patient identification and treatment; and clarity on PRV issuance and monetisation.

What this report is – and is not

This report is based exclusively on public information from Rocket Pharmaceuticals’ SEC filings (10-K, 10-Q, 8-K), official company press releases, investor presentations, ClinicalTrials.gov records and reputable news outlets covering biopharma and rare disease. It reflects a synthesis and interpretation of those sources for educational purposes only and does not incorporate any non-public or insider information. Some sections, notably the scenario analysis and health score, inevitably involve judgement and stylised assumptions; they are intended to help readers organise their thinking, not to provide price targets or trading recommendations.

Nothing in this text is, or should be construed as, investment advice, a solicitation, an offer to buy or sell any security, or a personalised recommendation under US SEC or EU/CONSOB regulations. Gene therapy, small-cap biotech and single-catalyst trading are inherently high-risk activities; readers should do their own research, consult qualified financial professionals where appropriate and never trade on a single report or catalyst calendar.